Office of the Vice President for Research

Cornovus Pharmaceuticals

Cornovus Pharmaceuticals logo

A new target and class of agents to treat cardiac failure

Cornovus Pharmaceuticals, Inc. commenced operations in October of 2011.  The company is focused on the development of a novel cardioprotective compound, MRS2339, for the treatment of heart failure.  MRS2339 is a small molecule that stimulates cardiac myocyte P2X4 receptors, which in turn increases myocyte eNOS and cGMP.  The compound has been shown effective in multiple preclinical models of heart failure and currently is progressing through IND enabling studies.

Contact

Bruce T.  Liang, M.D., Founder
Glenn R. Mattes, CEO
James Heym, Ph.D, CSO
Mark Van Allen, VP Finance